Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration

Pharmacological Research

Volumn 93, Issue , 2015, Pages 22-27

  Habib, Anwer ^a   Finn, Aloke V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti platelet therapy; Coronary artery disease; Endothelialization; Stents

Indexed keywords

ANTITHROMBOCYTIC AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANTICOAGULANT THERAPY; BARE METAL STENT; BLOOD VESSEL REACTIVITY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY STENTING; DRUG EFFICACY; DRUG ELUTING CORONARY STENT; DUAL ANTIPLATELET THERAPY; ENDOTHELIALIZATION; EVEROLIMUS ELUTING CORONARY STENT; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIROLIMUS ELUTING CORONARY STENT; STENT THROMBOSIS; THROMBOSIS PREVENTION; TISSUE REGENERATION; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM; WOUND HEALING IMPAIRMENT; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; DRUG ELUTING STENT; THROMBOSIS;

ANIMALS; ATHEROSCLEROSIS; DRUG-ELUTING STENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS; TOR SERINE-THREONINE KINASES;

EID: 84983094533     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.12.003     Document Type: Review

References (38)

1. D. Lloyd-Jones, R. Adams, M. Carnethon, G. De Simone, T.B. Ferguson, K. Flegal et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 119 3 2009 480 486
2. J.W. Moses, M.B. Leon, J.J. Popma, P.J. Fitzgerald, D.R. Holmes, C. O'Shaughnessy et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 14 2003 1315 1323
3. G.W. Stone, S.G. Ellis, D.A. Cox, J. Hermiller, C. O'Shaughnessy, J.T. Mann et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 3 2004 221 231
4. E.P. McFadden, E. Stabile, E. Regar, E. Cheneau, A.T. Ong, T. Kinnaird et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy Lancet 364 9444 2004 1519 1521
5. I. Iakovou, T. Schmidt, E. Bonizzoni, L. Ge, G.M. Sangiorgi, G. Stankovic et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 17 2005 2126 2130
6. M. Joner, A.V. Finn, A. Farb, E.K. Mont, F.D. Kolodgie, E. Ladich et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 1 2006 193 202
7. A.V. Finn, M. Joner, G. Nakazawa, F. Kolodgie, J. Newell, M.C. John et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization Circulation 115 18 2007 2435 2441
8. J. Kotani, M. Awata, S. Nanto, M. Uematsu, F. Oshima, H. Minamiguchi et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings J Am Coll Cardiol 47 10 2006 2108 2111
9. J. Daemen, P. Wenaweser, K. Tsuchida, L. Abrecht, S. Vaina, C. Morger et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 9562 2007 667 678
10. M. Joner, G. Nakazawa, A.V. Finn, S.C. Quee, L. Coleman, E. Acampado et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents J Am Coll Cardiol 52 5 2008 333 342
11. F. Otsuka, M. Vorpahl, M. Nakano, J. Foerst, J.B. Newell, K. Sakakura et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans Circulation 129 2 2014 211 223
12. K.W. Park, S.H. Kang, M.A. Velders, D.H. Shin, S. Hahn, W.H. Lim et al. Safety and efficacy of everolimus- versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials Am Heart J 165 2 2013 241 250 (e244)
13. B.K. Kim, J.S. Kim, J. Park, Y.G. Ko, D. Choi, Y. Jang et al. Comparison of optical coherence tomographic assessment between first- and second-generation drug-eluting stents Yonsei Med J 53 3 2012 524 529
14. M. Laplante, D.M. Sabatini mTOR signaling in growth control and disease Cell 149 2 2012 274 293
15. A.B. Brillantes, K. Ondrias, A. Scott, E. Kobrinsky, E. Ondriasova, M.C. Moschella et al. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein Cell 77 4 1994 513 523
16. B.E. Bierer, P.S. Mattila, R.F. Standaert, L.A. Herzenberg, S.J. Burakoff, G. Crabtree et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin Proc Natl Acad Sci USA 87 23 1990 9231 9235
17. A. Habib, V. Karmali, R. Polavarapu, H. Akahori, M. Nakano, S. Yazdani et al. Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation J Am Coll Cardiol 61 9 2013 971 980
18. T.L. Phung, K. Ziv, D. Dabydeen, G. Eyiah-Mensah, M. Riveros, C. Perruzzi et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin Cancer Cell 10 2 2006 159 170
19. P. Carmeliet, M.G. Lampugnani, L. Moons, F. Breviario, V. Compernolle, F. Bono et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis Cell 98 2 1999 147 157
20. A.V. Finn, F.D. Kolodgie, J. Harnek, L.J. Guerrero, E. Acampado, K. Tefera et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents Circulation 112 2 2005 270 278
21. R. Virmani, G. Guagliumi, A. Farb, G. Musumeci, N. Grieco, T. Motta et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109 6 2004 701 705
22. G. Nakazawa, A.V. Finn, M. Vorpahl, E.R. Ladich, F.D. Kolodgie, R. Virmani Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents J Am Coll Cardiol 57 4 2011 390 398
23. A. Habib, V. Karmali, M.C. John, R. Polavarapu, G. Nakazawa, K. Pachura et al. Everolimus-eluting stents improve vascular response in a diabetic animal model Circ Cardiovasc Interventions 7 4 2014 526 532
24. G. Nakazawa, M. Vorpahl, A.V. Finn, J. Narula, R. Virmani One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis JACC Cardiovasc Imaging 2 5 2009 625 628
25. G. Nakazawa, F. Otsuka, M. Nakano, M. Vorpahl, S.K. Yazdani, E. Ladich et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents J Am Coll Cardiol 57 11 2011 1314 1322
26. A. Habib, V. Karmali, R. Polavarapu, H. Akahori, Q. Cheng, K. Pachura et al. Sirolimus-FKBP12.6 impairs endothelial barrier function through protein kinase C-alpha activation and disruption of the p120-vascular endothelial cadherin interaction Arterioscler Thromb Vasc Biol 33 10 2013 2425 2431
27. P. Geraldes, G.L. King Activation of protein kinase C isoforms and its impact on diabetic complications Circ Res 106 8 2010 1319 1331
28. E.L. Eisenstein, K.J. Anstrom, D.F. Kong, L.K. Shaw, R.H. Tuttle, D.B. Mark et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation JAMA 297 2 2007 159 168
29. M. Valgimigli, G. Campo, M. Monti, P. Vranckx, G. Percoco, C. Tumscitz et al. Prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study I. short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 16 2012 2015 2026
30. S.J. Park, D.W. Park, Y.H. Kim, S.J. Kang, S.W. Lee, C.W. Lee et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents N Engl J Med 362 15 2010 1374 1382
31. F. Feres, R.A. Costa, A. Abizaid, M.B. Leon, J.A. Marin-Neto, R.V. Botelho et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial JAMA 310 23 2013 2510 2522
32. J.P. Collet, J. Silvain, O. Barthelemy, G. Range, G. Cayla, E. Van Belle et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial Lancet 384 9954 2014 1577 1585
33. L. Mauri, D.J. Kereiakes, R.W. Yeh, P. Driscoll-Shempp, D.E. Cutlip, P.G. Steg et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents N Engl J Med 371 23 2014 2155 2166
34. K.N. Garratt, W.D. Weaver, R.D. Jenkins, T.K. Pow, L. Mauri, D.J. Kereiakes et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after Taxus Liberte paclitaxel-eluting coronary stent placement Circulation 2014 pii: CIRCULATIONAHA.114.013570. [Epub ahead of print]
35. H.C. Gwon, J.Y. Hahn, K.W. Park, Y.B. Song, I.H. Chae, D.S. Lim et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study Circulation 125 3 2012 505 513
36. B.K. Kim, M.K. Hong, D.H. Shin, C.M. Nam, J.S. Kim, Y.G. Ko et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet therapy following Endeavor zotarolimus-eluting stent implantation) J Am Coll Cardiol 60 15 2012 1340 1348
37. A. Colombo, A. Chieffo, A. Frasheri, R. Garbo, M. Masotti-Centol, N. Salvatella et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial J Am Coll Cardiol 64 20 2014 2086 2097
38. M. Gilard, P. Barragan, A.A. Noryani, H.A. Noor, T. Majwal, T. Hovasse et al. Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial J Am Coll Cardiol 2014 10.1016/j.jacc.2014.11.008 pii: S0735-1097(14)06970-8. [Epub ahead of print]